Related Experiment Video
Updated: Jul 12, 2025
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
Literature analysis of cutaneous adverse reactions induced by tislelizumab
Qingli Guo1, Lili Jin2, Tingting Zhang1
1Department of Pharmacy, Weifang People's Hospital, Weifang, China.
Objective:
Tislelizumab may induce immune-related adverse events, especially adverse skin events. Early detection and timely intervention of cutaneous adverse events are crucial to improve patients' quality of life and reduce the disruption of therapeutic regimens. This study aimed to determine the clinical characteristics of cutaneous adverse reactions to tislelizumab and offer a reference for its rational clinical use.
Methods:
Case reports of cutaneous adverse reactions induced by tislelizumab were collected from the relevant databases (up to 31 March 2023). Patient age, sex, primary disease, medication use, occurrence of adverse skin conditions, treatment, and outcomes were recorded and descriptively analysed.
Results:
A total of 13 patients were enrolled, including six males and seven females, aged 55-79 years, with a median age of 75 years and a mean age of 70.92 ± 8.84 years. The original disease was lung carcinoma in none patients, cervical carcinoma in two, and urothelial carcinoma and squamous cell carcinoma in one each. The time from the initiation of medication use to the occurrence of cutaneous adverse reactions ranged from 7 to 177 days. Among the 13 patients, 10 showed improvement after drug withdrawal or symptomatic treatment. Two patients died (one died of disease progression and multiorgan failure, one died of acute coronary syndrome), and one patient's adverse skin reactions persisted without treatment.
Conclusions:
Tislelizumab-related cutaneous adverse reactions mostly occur after several days to months of treatment. In clinical practice, evaluation and monitoring should be strengthened. More attention should be paid to erythema and rashes, which may be signs of serious adverse skin reactions. Early detection and intervention can ensure the safe use of drugs and provide greater clinical benefits to patients.
Insights
Tislelizumab can cause skin reactions, often appearing months after treatment begins. Early detection of rashes and erythema is key for safe and effective cancer therapy.
Area of Science:
- Oncology
- Dermatology
- Immunotherapy
Background:
- Tislelizumab, an immunotherapy drug, can cause immune-related adverse events, particularly skin reactions.
- Prompt identification and management of cutaneous adverse events are vital for patient quality of life and treatment adherence.
Purpose of the Study:
- To characterize the clinical presentation of skin reactions associated with tislelizumab.
- To provide a clinical reference for the safe and rational use of tislelizumab.
Main Methods:
- A descriptive analysis of case reports on tislelizumab-induced cutaneous adverse reactions was performed.
- Data collected included patient demographics, primary disease, medication details, adverse skin event characteristics, treatment, and outcomes.
Main Results:
- Thirteen patients (6 male, 7 female; age 55-79) experienced skin reactions 7-177 days after starting tislelizumab.
- Most common reactions included erythema and rashes; 10 patients improved with treatment or drug withdrawal.
- Two patients died from unrelated causes, and one had persistent skin reactions.
Conclusions:
- Tislelizumab-related skin reactions typically manifest several days to months into treatment.
- Close monitoring for erythema and rashes is recommended as potential indicators of severe reactions.
- Early intervention is crucial for ensuring patient safety and maximizing therapeutic benefits.
